Interference of ATP‐Adenosine Axis by Engineered Biohybrid for Amplifying Immunogenic Cell Death‐Mediated Antitumor Immunotherapy
Top Cited Papers
- 18 July 2024
- journal article
- research article
- Published by Wiley in Advanced Materials
- Vol. 36 (36) , e2405673
Abstract
Immunogenic cell death (ICD) often results in the production and accumulation of adenosine (ADO), a byproduct that negatively impacts the therapeutic effect as well as facilitates tumor development and metastasis. Here, an innovative strategy is elaborately developed to effectively activate ICD while avoiding the generation of immunosuppressive adenosine. Specifically, ZIF‐90, an ATP‐responsive consumer, is synthesized as the core carrier to encapsulate AB680 (CD73 inhibitor) and then coated with an iron‐polyphenol layer to prepare the ICD inducer (AZTF), which is further grafted onto prebiotic bacteria via the esterification reaction to obtain the engineered biohybrid (Bc@AZTF). Particularly, the designed Bc@AZTF can actively enrich in tumor sites and respond to the acidic tumor microenvironment to offload AZTF nanoparticles, which can consume intracellular ATP (iATP) content and simultaneously inhibit the ATP‐adenosine axis to reduce the accumulation of adenosine, thereby alleviating adenosine‐mediated immunosuppression and strikingly amplifying ICD effect. Importantly, the synergy of anti‐PD‐1 (αPD‐1) with Bc@AZTF not only establishes a collaborative antitumor immune network to potentiate effective tumoricidal immunity but also activates long‐lasting immune memory effects to manage tumor recurrence and rechallenge, presenting a new paradigm for ICD treatment combined with adenosine metabolism.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFB3804600)
- Fundamental Research Funds for the Central Universities (2042023kfyq05)
- National Natural Science Foundation of China (52073218, 52273301, 22135005, 51873162, 51988102)
This publication has 53 references indexed in Scilit:
- Sonodynamic Cytokine Nanocomplexes with Specific Stimulation towards Effector T Cell for Combination Cancer ImmunotherapyAngewandte Chemie International Edition, 2023
- Bacteria‐Derived Outer‐Membrane Vesicles Hitchhike Neutrophils to Enhance Ischemic Stroke TherapyAdvanced Materials, 2023
- Fluorination‐Induced Multi‐Enhancement of a Nano‐Photosensitizer for Deep Photodynamic Therapy against Hypoxia TumorAdvanced Functional Materials, 2023
- Mitochondria‐Targeted Photodynamic and Mild‐Temperature Photothermal Therapy for Realizing Enhanced Immunogenic Cancer Cell Death via Mitochondrial StressAdvanced Functional Materials, 2023
- Pyroptosis‐Mediated Synergistic Photodynamic and Photothermal Immunotherapy Enabled by a Tumor‐Membrane‐Targeted Photosensitive DimerAdvanced Materials, 2023
- HXV2O5 Nanocatalysts Combined with Ultrasound for Triple Amplification of Oxidative Stress to Enhance Cancer Catalytic TherapyAngewandte Chemie International Edition, 2022
- The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibitionJournal of Cancer Research and Clinical Oncology, 2022
- Bacteria‐Based Cancer ImmunotherapyAdvanced Science, 2021
- CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaCancer Immunology, Immunotherapy, 2021
- Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic SclerosisArthritis & Rheumatology, 2020